Bio-Techne Corporation TECH
Composite 64/100; the shares have moved about 53% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 27/100 — a moderate mark against it.
Balance-sheet strength ranks 90/100 — a strong point in its favour. Momentum ranks 87/100 — a strong point in its favour. Growth ranks 66/100 — a moderate point in its favour.
Valuation ranks 27/100 — a moderate mark against it. Income ranks 39/100 — a slight mark against it.
What the company does Bio-Techne develops and sells life-science reagents, instruments, and diagnostics across Protein Sciences (cytokines, antibodies, automated protein analysis tools) and Diagnostics & Spatial Biology (exosome assays, in-situ hybridization, oncology kits).
Key financials Gross margin 65.8%, operating margin 23.4%, net margin 15.0%. ROE 9.0%, ROA 6.1%, ROCE 10.2%. Revenue growth -0.4%, EPS growth 152.0%. Debt/Equity 0.14, current ratio 4.55, interest coverage 45.53.
Stock health Overall Sideravia score 61.7 (average quality, rich valuation, positive momentum). Strength 86.9, Momentum 87.4, Growth 66.7. Piotroski F-Score 7/9. RSI(14) 71.20, 0.19% below 52-week high.
Price vs fair value The stock trades at a PREMIUM of 3.80% versus the analyst mean target of 69.73. - Analyst mean target implies 3.80% upside (analyst mean target) - High forward P/E 34.48 and PEG 0.43 (Valuation anchor) - Recent cautionary coverage: “3 High-Flying Stocks We Approach with Caution” (StockStory) - Bullish sentiment headline: “Is Wall Street Bullish or Bearish on Bio-Techne Stock?” (Barchart)
Looking forward Forward P/E 34.48 and PEG 0.43 suggest rich near-term valuation despite strong momentum and growth scores. EPS growth of 152.0% underpins part of the premium.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.